This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?
EASD
Hybrid
2022
Symposium

Date and time:

20.09.22 at 18:00-19:00 CEST

Type:

Congress:
Speakers:

Welcome and introduction

Cardiovascular risk: what’s weight got to do with it?

Improvements in cardiovascular risk factors: STEP by STEP

SELECT and STEP-HFpEF: new horizons

Panel discussion

Closing

John Deanfield

John Deanfield

University College, London, UK


John Deanfield FRCP FESC is a Professor of Cardiology at University College London. He is Director of the National Institute of Cardiovascular Outcomes Research (NICOR) in the UK and was a Senior Advisor to the Office for Health Improvement and Disparities (formally Public Health England) on cardiovascular disease prevention. In his role within NICOR, Deanfield has played a leading role in the use of national data to improve outcomes from heart disease. He has championed the idea of lifetime benefits of sustained management of cardiovascular risk factors and comorbidities, introducing the concept of 'investing in your arteries'.

 

Deanfield's career has focused on the management of heart disease across the lifetime of an individual. He completed his clinical training at the Middlesex Hospital London. He then carried out his postgraduate training at Great Ormond Street Hospital (GOSH) in paediatric cardiology and at the Royal Postgraduate Medical School Hammersmith Hospital, London, in adult cardiology, which allowed him to understand cardiovascular disease in its different stages and progression.

 

Deanfield was appointed a Consultant Cardiologist at GOSH in 1984. A key contributor to the new speciality of Adult Congenital Heart Disease, he chaired the National and International Practice Guidelines, including the European Society of Cardiology Task Force for Grown Up Congenital Heart Disease (GUCH) (2003). At The National Heart Hospital, he developed one of the largest programmes for Adult Congenital Heart Disease (ACHD/GUCH) in the world, which was transferred to create a new unit at the new Barts Heart Centre in 2015. He chaired the Standards Committee for Adults in the UK National ‘Safe and Sustainable’ Review of Congenital Heart Disease services in 2014 and advised on subsequent implementation.

 

As Director of NICOR since 2011, Deanfield oversees one of the largest longitudinal set of cardiovascular electronic health records in the world, providing UK-wide data for NHS Quality Improvement, research and public engagement. He has actively worked towards improvements to cardiology, working on prevention, clinical care and the evaluation of outcomes.

 

He has published more than 520  research articles (H-index 140, citations >139K), ranging across the consequences of congenital heart disease to the early onset of acquired cardiovascular disease in adults. Deanfield developed a non-invasive technique to study the factors responsible for early arterial disease and its response to treatment. In 2014, he chaired the JBS3 Cardiovascular Prevention Guidelines, introducing the concept of ‘investing in your arteries’ to communicate with patients. This in turn led to the development in 2018 of the Heart Age Calculator to extend this messaging to the general public, in collaboration with PHE and NHS England.  He is currently Chairing the development of the JBS4 guidelines.   Deanfield co-chaired the Expert Scientific and Clinical Advisory Panel (ESCAP) for the Health Check Programme in PHE as well as the Academic Group on Healthy Ageing in PHE.

 

Deanfield was awarded a British Heart Foundation Chair to study cardiovascular disease prevention (2003-2018). He became adjunct Professor at Yale University, New Haven USA in 2009 and was given an Einstein Professorship (2018-2021) at the Hospital Charite Universitätsmedizin Berlin to study Artificial Intelligence in large scale cardiovascular data. Deanfield was elected a Fellow of the Academy of Medical Sciences (FMedSci) in 2001, and in 2017 he was awarded the British Cardiovascular Society Mackenzie medal in recognition of outstanding service to British Cardiology.   In 2021 he was awarded the Commander of the Order of the British Empire (CBE).

 

Deanfield sits on the Medical Advisory Committees and Boards of a number of healthcare companies. He is Chief Medical Advisor to the new national early disease detection programme, ‘Our Future Health’ (2020) and Chaired the National Health Check Programme Review that was published in 2021. His charity positions include membership of the Medical Advisory Board of the Chain of Hope Charity and Academic Committee Chair of Heart(UK). For many years, Deanfield was Medical Advisor to the Somerville Foundation for Adult Congenital Heart Disease patients.


Read full bio
Micheal Lincoff

Micheal Lincoff

Heart, Vascular, and Thoracic Institute of the Cleveland Clinic, Ohio, USA


Dr. Lincoff is Vice Chairman for Research and an interventional cardiologist in the Heart, Vascular, and Thoracic Institute of the Cleveland Clinic.  

He is the Director of C5Research, the Cleveland Clinic Coordinating Center for Clinical Research, an academic research organization which plans, coordinates, and manages multicenter clinical trials of new pharmacologic or device therapies.  Dr. Lincoff’s research activities focus on development of therapies to reduce acute and long-term complications of percutaneous coronary revascularization procedures, optimize management of acute coronary ischemic syndromes, or reduce progression or complications of atherosclerosis.  He has served as principal investigator or steering committee member of over 50 trials in ischemic and cardiometabolic diseases.

Dr. Lincoff also supervises clinical research activities throughout the Cleveland Clinic as Director of the Center for Clinical Research of the Lerner Research Institute.  He is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.  He holds the Charles and Charlotte Fowler Endowed Chair for Cardiovascular Research at the Cleveland Clinic.

Dr. Lincoff has authored or coauthored over 350 peer-reviewed articles, authored over 80 book chapters and reviews, and presented lectures at various medical meetings and courses throughout the world.   He has served as the Chair of the Cardiovascular and Renal Drugs Advisory Committee of the United States Food and Drug Administration.

Dr. Lincoff earned his undergraduate BS degree in chemical and biomedical engineering at Carnegie Mellon University in 1982 and his MD from Johns Hopkins University in 1986.  He completed a residency in internal medicine at Beth Israel Hospital, Harvard Medical School, a fellowship in cardiovascular diseases at the University of Michigan Medical Center, and a fellowship in interventional cardiology at the Cleveland Clinic.  He is a fellow of the American College of Cardiology and a member of the American Heart Association and the Sigma Xi Scientific Research Society. 

 


Read full bio

Related